Clinical Comfort Evaluation of Two Marketed Spherical Contact Lenses
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35216
- Schaeffer Eye Associates
-
-
Florida
-
Jacksonville, Florida, United States, 32256
- Beaches Family Eyecare
-
-
Louisiana
-
Lafayette, Louisiana, United States, 70503
- Todays Eyecare, LLC
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Based on his/her knowledge, must be in good general health.
- Be 18 to 38 years old.
- Be able and willing to adhere to the instructions set forth in this protocol and complete all specified evaluation.
- Read, indicate understanding of, and sign Written Informed Consent.
- Be existing or successfully adapted users of soft contact lenses, but not currently wearing either of the study lenses (Avaira or Oasys) being evaluated in this trial.
- Require a visual correction in both eyes.
- Require a prescription between +8.00D and -12.00D and have less than or equal to 0.75D of astigmatism in both eyes.
- Achieve visual acuity of 20/25 or better in each eye with a spherical contact lens prescription.
Have normal eyes with no evidence of abnormality or disease. For the purposes of this study a normal eye is defined as one having:
- No amblyopia.
- No evidence of lid abnormality or infection (e.g. entropion, ectropion, chalazia, recurrent styes).
- lamp findings Grade 2 or above: corneal edema, tarsal abnormalities, and conjunctival injection).
- No other active ocular disease (e.g. glaucoma, history of recurrent corneal erosions, cornea [infiltrates], conjunctiva, lids, and intraocular infection or inflammation of an allergic, bacterial, or viral etiology).
- No aphakia.
Exclusion Criteria:
- 0.75D or greater of refractive astigmatism in either eye.
- Presbyopic or current monovision contact lens wear.
- Cannot be currently wearing either lenses (Avaira or Oasys).
- Presence of clinically significant (grade 2-4) anterior segment abnormalities; inflammation such as iritis; or any infection of the eye, lids, or associated structures.
- Presence of ocular or systemic disease or need of medication which might interfere with contact lens wear.
Slit lamp findings that would contraindicate contact lens wear such as:
- Pathological dry eye or associated findings
- Pterygium, pinguecula or corneal scars within the visual axis
- Neovascularization > 0.75 mm in from the limbus
- Giant papillary conjunctivitis (GPC) worse than Grade 1
- Anterior uveitis or iritis (past or present)
- Seborrheic eczema, seborrheic conjunctivitis
- History of corneal ulcer or fungal infections
- Poor personal hygiene
- A known history of corneal hypoesthesia (reduced corneal sensitivity)
- Contact Lens best corrected Snellen visual acuities (VA) worse than 20/30.
- Aphakia, Keratoconus or a highly irregular cornea.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: enfilcon A
participants randomized to wear the Enfilcon A (test) lens in one eye and Senofilcon A (control) lens in the other eye.
|
Test lens
Control lens
|
|
Active Comparator: senofilcon A
participants randomized to wear the Enfilcon A (test) lens in one eye and Senofilcon A (control) lens in the other eye.
|
Test lens
Control lens
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Comfort at Insertion
Time Frame: Baseline
|
Participant's response for comfort at insertion.
(Scale 0-10; 0=poor/intolerable, 10=comfortable/ cannot be felt) Obtained at baseline.
|
Baseline
|
|
Comfort at Insertion
Time Frame: 15 minutes
|
Participant's response for comfort at 15 minutes.
(Scale 0-10; 0=poor/intolerable, 10=comfortable/ cannot be felt) Obtained at 15 minutes.
|
15 minutes
|
|
Comfort Preference
Time Frame: Baseline
|
Participant's response for comfort preference of enfilcon A (test) lens, senofilcon A(control) lens at insertion.
|
Baseline
|
|
Comfort Preference
Time Frame: 15 minutes
|
Participant's response for comfort of enfilcon A (test) lens, senofilcon A (control) lens at 15 minutes wear.
|
15 minutes
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Donald Siegel, OD, Coopervision, Inc.
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- EX-MKTG-38-MTF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.